Proactive Investors - Run By Investors For Investors

Hikma sounds the earnings alarm sending shares crashing

A tough and competitive market hit the firm's Generics business
Hikma sounds the earnings alarm sending shares crashing
Hikma certainly wasn't the investment to be in this morning!

Shares in Hikma Pharmaceuticals (LON:HIK) were marked down 7% after the company lowered guidance for sales of generic products and warned of an “increasingly challenging environment”.

The competition in this particular arena has meant the company has been forced progressively chop back its revenue estimate for the unit, which now stands at US$620mln for the year; in April the figure was US$800mln.

Total revenues are set to be in the order of US$2bn.

Interim results from the FTSE 250 ‘druggie’, which also specialises in injectable products, were lacklustre with sales up 1% at US$895mln, bit operating profits off US$8mln at US$113mln.

Tough market

“In the US, where competition is increasing and pricing pressure is intensifying, sales in our Injectables business were resilient and we maintained our track record of strong profitability,” said chairman Said Darwazah.

“The tougher market conditions did however continue to limit growth in our Generics business. 

“We remain focused on executing our Generics strategy and we have strengthened the management team and further restructured the cost base to provide a robust and efficient platform to support pipeline execution and future growth.”

The shares, off 35% in the year to date, fell 95.96p to 1,227p, valuing the business at just under £3bn.

Strenghens Takeda ties

Separately, Hikma said it has strengthened ties with Japanese giant Takeda by expanding its licensing and distribution agreement in the Middle East and North Africa (MENA).

The two will focus their expertise on promoting cardiovascular and diabetes treatments, according to Mazen Darwazah, the company’s head of emerging markets.  

“We are pleased to be building on our partnership with Takeda to bring important medicines to the MENA region,” he added.

“By working with global partners we are strengthening our product portfolio in growing therapeutic areas and reinforcing our commitment to improving patient access to quality medicines."

View full HIK profile View Profile

Hikma Pharmaceuticals Timeline

Related Articles

Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use